[1]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[2]
|
Herbst, R.S., Heymach, J.V. and Lippman, S.M. (2008) Lung Cancer. New England Journal of Medicine, 359, 1367-1380. https://doi.org/10.1056/NEJMra0802714
|
[3]
|
Simeone, J.C., Nordstrom, B.L., Patel, K., et al. (2019) Treatment Patterns and Overall Survival in Metastatic Non-Small-Cell Lung Cancer in a Real-World, US setting. Future Oncology, 15, 3491-3502. https://doi.org/10.2217/fon-2019-0348
|
[4]
|
SEER [Surveillance, Epidemiology, and End Results] (2015) Cancer Statistics Factsheets: Lung and Bronchus Cancer. http://seer.cancer.gov/statfacts/html/lungb.html
|
[5]
|
Goldstraw, P., Crowley, J., Chansky, K., et al. (2007) The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal of Thoracic Oncology, 2, 706-714.
https://doi.org/10.1097/JTO.0b013e31812f3c1a
|
[6]
|
Pignon, J.P., Tribodet, H., Scagliotti, G.V., et al. (2008) Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26, 3552-3559. https://doi.org/10.1200/JCO.2007.13.9030
|
[7]
|
Thomas, M., Rübe, C., Hoffknecht, P., et al. (2008) German Lung Cancer Cooperative Group. Effect of Preoperative Chemoradiation in Addition to Preoperative Chemotherapy: A Randomized Trial in Stage III Non-Small-Cell Lung Cancer. The Lancet Oncology, 9, 636-648. https://doi.org/10.1016/S1470-2045(08)70156-6
|
[8]
|
Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. (2012) Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 366, 2455-2465. https://doi.org/10.1056/NEJMoa1200694
|
[9]
|
Motzer, R.J., Tannir, N.M., McDermott, D.F., et al. (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 378, 1277-1290. https://doi.org/10.1056/NEJMoa1712126
|
[10]
|
Robert, C., Long, G.V., Brady, B., et al. (2015) Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New England Journal of Medicine, 372, 320-330.
https://doi.org/10.1056/NEJMoa1412082
|
[11]
|
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2019) Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 381, 1535-1546. https://doi.org/10.1056/NEJMoa1910836
|
[12]
|
Reck, M., Remon, J. and Hellmann, M.D. (2022) First-Line Immunotherapy for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 586-597.
https://doi.org/10.1200/JCO.21.01497
|
[13]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375, 1823-1833. https://doi.org/10.1056/NEJMoa1606774
|
[14]
|
Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., et al. (2019) Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 381, 2020-2031. https://doi.org/10.1056/NEJMoa1910231
|
[15]
|
Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., et al. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378, 2078-2092. https://doi.org/10.1056/NEJMoa1801005
|
[16]
|
Herbst, R.S., Baas, P., Kim, D.W., et al. (2016) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomized Controlled Trial. Lancet, 387, 1540-1550.
https://doi.org/10.1016/S0140-6736(15)01281-7
|
[17]
|
Antonia, S.J., Villegas, A., Daniel, D., et al. (2018) PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 379, 2342-2350. https://doi.org/10.1056/NEJMoa1809697
|
[18]
|
Spigel, D.R., Faivre-Finn, C., Gray, J.E., et al. (2022) Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer. Journal of Clinical Oncology, 40, 1301-1311.
https://doi.org/10.1200/JCO.21.01308
|
[19]
|
Steuer, C.E. and Ramalingam, S.S. (2021) Advances in Immunotherapy and Implications for Current Practice in Non–Small-Cell Lung Cancer. JCO Oncology Practice, 17, 662-668. https://doi.org/10.1200/OP.21.00305
|
[20]
|
Zhu, J., Li, R., Tiselius, E., et al. (2017) Immunotherapy (Excluding Checkpoint Inhibitors) for Stage I to III Non-Small Cell Lung Cancer Treated with Surgery or Radiotherapy with Curative Intent. Cochrane Database of Systematic Reviews, No. 12, Article No. CD011300. https://doi.org/10.1002/14651858.CD011300.pub2
|
[21]
|
Chaft, J.E., Rimner, A., Weder, W., et al. (2021) Evolution of Systemic Therapy for Stages I-III Non-Metastatic Non-Small-Cell Lung Cancer. Nature Reviews Clinical Oncology, 18, 547-557. https://doi.org/10.1038/s41571-021-00501-4
|
[22]
|
Paz-Ares, L., O’Brien, M.E.R., Mauer, M., et al. (2022) VP3-2022: Pembrolizumab (Pembro) versus Placebo for Early-Stage Non-Small Cell Lung Cancer (NSCLC) Following Complete Resection and Adjuvant Chemotherapy (Chemo) When Indicated: Randomized, Triple-Blind, Phase III EORTC-1416-LCG/ETOP 8-15—PEARLS/KEYNOTE-091 Study. Annals of Oncology, 33, 451-453.
https://doi.org/10.1016/j.annonc.2022.02.224
|
[23]
|
Felip, E., Altorki, N., Zhou, C., et al. (2021) Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial. Lancet, 398, 1344-1357. https://doi.org/10.1016/S0140-6736(21)02098-5
|
[24]
|
O’Brien, M.E.R., Paz-Ares, L., Jha, N., et al. (2022) EORTC-1416-LCG/ETOP 8-15—PEARLS/KEYNOTE-091 Study of Pembrolizumab versus Placebo for Completely Resected Early-Stage Non-Small Cell Lung Cancer (NSCLC): Outcomes in Subgroups Related to Surgery, Disease Burden, and Adjuvant Chemotherapy Use. Journal of Clinical Oncology, 40, 8512.
https://doi.org/10.1200/JCO.2022.40.16_suppl.8512
|
[25]
|
Wakelee, H.A., Altorki, N.K., Zhou, C., et al. (2021) IMpower010: Primary Results of a Phase III Global Study of Atezolizumab versus Best Supportive Care after Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 39, 8500.
https://doi.org/10.1200/JCO.2021.39.15_suppl.8500
|
[26]
|
Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J.R., Bharat, A., et al. (2022) Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 497-530. https://www.nccn.org
|
[27]
|
NCT02273375. Double Blind Placebo Controlled Study of Adjuvant MEDI14736 in Completely Resected NSCLC. https://www.clinicaltrials.gov
|
[28]
|
NCT04385368. Phase III Study to Determine the Efficacy of Durvalumab in Combination with Chemotherapy in Completely Resected Stage II-III Non-Small Cell Lung Cancer (NSCLC) (MERMAID-1). https://www.clinicaltrials.gov
|
[29]
|
Peters, S, Spigel, D., Ahn, M., Tsuboi, M., Chaft, J., Harpole, D., Goss, G., Arlesi, F.B., Abbosh, C., Polle, L., May, R., Dennis, P.A. and Swanton, C. (2021) P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery. Journal of Thoracic Oncology, 16, S258-S259. https://doi.org/10.1016/j.jtho.2021.01.376
|
[30]
|
NCT04642469. Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-Small Cell Lung Cancer (NSCLC) after Curative Intent Therapy. (MERMAID-2).
https://www.clinicaltrials.gov
|
[31]
|
Felip, E., Rosell, R., Maestre, J.A., et al. (2012) Preoperative Chemotherapy plus Surgery versus Surgery plus Adjuvant Chemotherapy versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 28, 3138-3145.
https://doi.org/10.1200/JCO.2009.27.6204
|
[32]
|
Liu, J., Blake, S.J., Yong, M.C., Harjunpää, H., Ngiow, S.F., Takeda, K., Young, A., O’Donnell, J.S., Allen, S., Smyth, M.J. and Teng, M.W. (2016) Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discovery, 6, 1382-1399.
https://doi.org/10.1158/2159-8290.CD-16-0577
|
[33]
|
Shu, C.A. and Cascone, T. (2021) What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 2855-2858. https://doi.org/10.1200/JCO.21.01446
|
[34]
|
Forde, P.M., Chaft, J.E., Smith, K.N., et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 378, 1976-1986.
https://doi.org/10.1056/NEJMoa1716078
|
[35]
|
Eichhorn, F., Klotz, L.V., Bischoff, H., et al. (2019) Neoadjuvant Anti-Programmed Death-1 Immunotherapy by Pembrolizumab in Resectable Nodal Positive Stage II/IIIa Non-Small-Cell Lung Cancer (NSCLC): The NEOMUN Trial. BMC Cancer, 19, Article No. 413. https://doi.org/10.1186/s12885-019-5624-2
|
[36]
|
Shu, C.A., Gainor, J.F., Awad, M.M., et al. (2020) Neoadjuvant Atezolizumab and Chemotherapy in Patients with Resectable Non-Small-Cell Lung Cancer: An Open-Label, Multicentre, Single-Arm, Phase II Trial. The Lancet Oncology, 21, 786-795. https://doi.org/10.1016/S1470-2045(20)30140-6
|
[37]
|
Gao, S., Li, N., Gao, S., et al. (2020) Neoadjuvant PD-1 Inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 15, 816-826.
https://doi.org/10.1016/j.jtho.2020.01.017
|
[38]
|
Rothschild, S.I., Zippelius, A., Eboulet, E.I., et al. (2021) SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA (N2) Non-Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. Journal of Clinical Oncology, 39, 2872-2880. https://doi.org/10.1200/JCO.21.00276
|
[39]
|
Spicer, J.W.C. and Tanaka, F. (2021) Surgical Outcomes from the Phase 3 CheckMate 816 Trial: Nivolumab (NIVO) + Platinum-Doublet Chemotherapy (Chemo) vs. Chemo alone as Neoadjuvant Treatment for Patients with Resectable Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 39, 8503.
https://doi.org/10.1200/JCO.2021.39.15_suppl.8503
|
[40]
|
Heymach, J.V., Taube, J.M., Mitusdomi, T., et al. (2019) P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC. Journal of Thoracic Oncology, 14, S625-S626.
https://doi.org/10.1016/j.jtho.2019.08.1318
|
[41]
|
Sepesi, B., Cascone, T., William, W., et al. (2019) OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Non-Small Cell Lung Cancer—NEOSTAR Study. Journal of Thoracic Oncology, 14, S241-S242.
https://doi.org/10.1016/j.jtho.2019.08.481
|
[42]
|
Cascone, T., William Jr., W.N., Weissferdt, A., et al. (2021) Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nature Medicine, 27, 504-514.
https://doi.org/10.1038/s41591-020-01224-2
|
[43]
|
Herbst, R.S., Majem, M., Barlesi, F., et al. (2022) COAST: An Open-Label, Phase, I.I., Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, Article ID: JCO2200227. Epub Ahead of Print. https://doi.org/10.1200/JCO.22.00227
|
[44]
|
NCT04092283. Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients with Unresectable Stage III NSCLC.
http://www.clinicaltrials.gov
|
[45]
|
NCT03801902. Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients with Stage II-III Non-Small Cell Lung Cancer. http://www.clinicaltrials.gov
|
[46]
|
Bernstein, M.B., Krishnan, S., Hodge, J.W., et al. (2016) Immunotherapy and Stereotactic Ablative Radiotherapy (ISABR): A Curative Approach? Nature Reviews Clinical Oncology, 13, 516-524. https://doi.org/10.1038/nrclinonc.2016.30
|
[47]
|
Luke, J.J., Lemons, J.M., Karrison, T.G., et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients with Advanced Solid Tumors. Journal of Clinical Oncology, 36, 1611-1618.
https://doi.org/10.1200/JCO.2017.76.2229
|
[48]
|
Theelen, W.S.M.E., Peulen, H.M.U., Lalezari, F., et al. (2019) Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs. Pembrolizumab alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncology, 5, 1276-1282.
https://doi.org/10.1001/jamaoncol.2019.1478
|
[49]
|
Campbell, A.M, Cai, W.L, Burkhardt, D., et al. (2019) Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology, Biology, Physics, 105, S36-S37. https://doi.org/10.1016/j.ijrobp.2019.06.453
|
[50]
|
Altorki, N.K., McGraw, T.E., Borczuk, A.C., et al. (2021) Neoadjuvant Durvalumab with or without Stereotactic Body Radiotherapy in Patients with Early-Stage Non-Small-Cell Lung Cancer: A Single-Centre, Randomised Phase 2 Trial. The Lancet Oncology, 22, 824-835. https://doi.org/10.1016/S1470-2045(21)00149-2
|
[51]
|
NCT03217071. Pembrolizumab with and without Radiotherapy for Non-Small Cell Lung Cancer. http://www.clinicaltrials.gov
|
[52]
|
NCT03446911. Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Planned for Surgery. http://www.clinicaltrials.gov
|
[53]
|
NCT03833154. Durvalumab vs Placebo with Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation. http://www.clinicaltrials.gov
|
[54]
|
Chang, J.Y., Lin, S.H., Yao, L., et al. (2020) I-SABR Phase II Randomized Study of Nivolumab Immunotherapy and Stereotactic Ablative Radiotherapy in Early Stage NSCLC: Interim Analysis Adverse Effects. Journal of Clinical Oncology, 38, 9035.
https://doi.org/10.1200/JCO.2020.38.15_suppl.9035
|
[55]
|
NCT03383302. SBRT with Immunotherapy in Early Stage Non-Small Cell Lung Cancer: Tolerability and Lung Effects. http://www.clinicaltrials.gov
|
[56]
|
Melillo, G., Chand, V., Yovine, A., et al. (2021) Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Advances in Therapy, 38, 2759-2778.
https://doi.org/10.1007/s12325-021-01675-0
|